| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We have been working that L-DOPA, a dopamine precursor has unique physiological activity. In 2017, Masukawa reported that L-DOPA receptor candidate, GPR-143, interact with alpha adrenergic receptor and modulating its action. Therefore, we have investigated at first that L-DOPA has any interaction to vasoconstriction of pulmonary artery. As a result we found that L-DOPA also enhance phenylephrine induced vasoconstriction in pulmonary artery. Moreover, interestingly, this action is attenuated in early stage of monocrotaline-induced pulmonary hypertensive rat model. This findings may yield novel pathological and therapeutic finding in pulmonary hypertension.
|
